Literature DB >> 3896518

Direct identification of prohormone conversion site in insulin-secreting cells.

L Orci, M Ravazzola, M Amherdt, O Madsen, J D Vassalli, A Perrelet.   

Abstract

We have localized proinsulin in B cells of human and rat pancreatic islets, using a proinsulin-specific monoclonal antibody revealed by immunocytochemistry. Proinsulin is abundant in Golgi stacks and clathrin-coated secretory granules. It rapidly disappears from these compartments when protein synthesis is inhibited. Depletion of ATP stores prevents movement of proinsulin from the Golgi stacks to the secretory granules; under these conditions, the prohormone in preformed coated granules is converted to insulin, whereas that bound to the Golgi complex is not. Non-coated granules show a low level of proinsulin reactivity under all incubation protocols. These findings provide direct evidence that coated secretory granules are the major, if not the only, cellular site of proinsulin to insulin conversion. They also suggest that the Golgi stack is not involved in conversion, and that intercisternal transport and coated granule formation are hitherto unrecognized energy-requiring steps that precede conversion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896518     DOI: 10.1016/0092-8674(85)90124-2

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  97 in total

1.  Insulin and C-peptide co-localization in the beta granules of normal human pancreas and insulinomas. A quantitative immunocytochemical approach.

Authors:  M Kalina; L Grimelius; B Cedermark; I Hammel
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

2.  Ultrastructural analysis of transitional endoplasmic reticulum and pre-Golgi intermediates: a highway for cars and trucks.

Authors:  Jing-Yu Fan; Jürgen Roth; Christian Zuber
Journal:  Histochem Cell Biol       Date:  2003-11-18       Impact factor: 4.304

3.  Mutant proinsulin that cannot be converted is secreted efficiently from primary rat beta-cells via the regulated pathway.

Authors:  Philippe A Halban; Jean-Claude Irminger
Journal:  Mol Biol Cell       Date:  2003-03       Impact factor: 4.138

Review 4.  Is there structural specificity in the reversible protein aggregates that are stored in secretory granules?

Authors:  Camille Keeler; Michael E Hodsdon; Priscilla S Dannies
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

5.  Insulin secretory granule biogenesis. Co-ordinate regulation of the biosynthesis of the majority of constituent proteins.

Authors:  P C Guest; E M Bailyes; N G Rutherford; J C Hutton
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

6.  Partial diversion of a mutant proinsulin (B10 aspartic acid) from the regulated to the constitutive secretory pathway in transfected AtT-20 cells.

Authors:  D J Gross; P A Halban; C R Kahn; G C Weir; L Villa-Komaroff
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

7.  Differences in glucose recognition by individual rat pancreatic B cells are associated with intercellular differences in glucose-induced biosynthetic activity.

Authors:  R Kiekens; P In 't Veld; T Mahler; F Schuit; M Van De Winkel; D Pipeleers
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

8.  Proinsulin intermolecular interactions during secretory trafficking in pancreatic β cells.

Authors:  Leena Haataja; Erik Snapp; Jordan Wright; Ming Liu; Alexandre B Hardy; Michael B Wheeler; Michele L Markwardt; Mark Rizzo; Peter Arvan
Journal:  J Biol Chem       Date:  2012-12-06       Impact factor: 5.157

9.  Effects of thioacetamide on pancreatic islet B-cell function.

Authors:  Willy J Malaisse; Philippe Lebrun; Abdullah Sener; Gerrit H J Wolters; Mariella Ravazzola
Journal:  Endocrine       Date:  2004-06       Impact factor: 3.633

Review 10.  Islet autoantigens: structure, function, localization, and regulation.

Authors:  Peter Arvan; Massimo Pietropaolo; David Ostrov; Christopher J Rhodes
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.